Short-term Clinical Effects Of Cisplatin Combined With Temozolomide In Treatment Of Gliomas With MGMT Gene Promotor Methylation Positive After Surgery

Objective The treatment of gliomas is a difficult in clinical of neurosurgery.So far,we have not find a good treatment for people with gliomas after surgery.To investigate the difference of short-term clinical effects in the treatment of gliomas with O~6-methylguanine DNA-transferase(MGMT)gene promotor methylation positive after surgery by cisplatin combined with temozolomide or temozolomide only.Method a total of 34 patients with pathologically confirmed gliomas(WHO II-IV)with MGMT gene promotor methylation positive were enrolled.All patients had pretreated with concurrent radiochemotherapy.The treatment group include 18 patients were treated with cisplatin plus temozolomide(TMZ).The control group include 16patients were treated with TMZ only.Result The objective response rate(ORR)was 66.66%in the treatment group,and the ORR was 31.25%in the control group.There was a significant difference.The incidence rate of epilepsy was 22.22%and 12.5%,respectively,in the treatment group and the control group.But,there was no significant difference.The common adverse reactions include neutropenia,decreased appetite,nausea,vomitting and increased creatinine.Conclusion:Scheme of cisplatin combined with TMZ after concurrent radiochemotherapy may improve efficacy in patients of gliomas with MGMT gene promotor mythelation positive,and the adverse reactions were tolerable.It is worth being generalized in clinical application.